Little Clinic sponsors fashion show to benefit children’s hospital
BRENTWOOD, Tenn. The Little Clinic, which operates retail-based health clinics within six Louisville Kroger stores, is sponsoring the 2009 American Girl Fashion Show, benefiting Kosair Children’s Hospital through the Children’s Hospital Foundation, the company has announced.
The American Girl Fashion Show, scheduled for Oct. 9 to 11, will benefit the Kosair Children?s Hospital neonatal intensive care unit. In its third year in Louisville, the weekend has raised more than $180,000 for the foundation.
“Being involved in the communities in which we serve has always been a driving part of who we are,” stated Lisa Loscalzo, president of The Little Clinic. “The Children’s Hospital Foundation offered The Little Clinic the chance to participate in this great event and we are very excited to join in the fundraising efforts for the first time. We hope that the added exposure we are able to give the event at our clinics generates increased awareness for the needs of the hospital and brings even more girls to the event.”
As part of its sponsorship, The Little Clinic is conducting an in-store ticket giveaway at each of six Louisville-area clinics in Kroger. In addition, The Little Clinic will host on Sept. 20 a free in-store tea and story reading featuring American Girl models at its location in the Stony Brook Kroger store.
Safeway adds two to board of directors
PLEASANTON, Calif. Safeway on Monday named Arun Sarin and Michael Shannon to the company’s board of directors. The company’s board of directors will expand from 10 to 12 members with these new appointments, the company stated.
“We are fortunate to have individuals with these credentials joining the board,” stated Safeway chairman, president and CEO Steve Burd. “[Sarin] and [Shannon] have each run substantial businesses, and their experience will be valuable to our board.”
Sarin has worked in the telecommunications industry for the majority of his career. Most recently, he was the CEO of Vodafone Group, one of the world’s largest mobile phone companies by revenue. Sarin has served on numerous boards including Gap, Charles Schwab and Cisco Systems. He recently retired from being a non-executive director of the Court of the Bank of England.
Shannon founded KSL Capital Partners in 2004 and its predecessor, KSL Recreation Corporation, in 1992, serving as its president and CEO. KSL Capital Partners is a U.S. private equity firm dedicated to investments in travel and leisure businesses. Shannon also founded and became CEO of KSL Resorts in 2004, following the sale of KSL Recreation. During his tenure as CEO, KSL Recreation grew to become one of the largest independent owners and operators of resorts. From 1986 to 1992, Shannon served as president and CEO of Vail Associates, owner of the Vail and Beaver Creek resorts in Colorado. He currently serves on the board of ING Direct, the Vail Valley Foundation, the United States Ski and Snowboard Association and Eisenhower Memorial Hospital.
IRI discusses health care during recession in new report
CHICAGO Information Resources Inc. on Thursday released a report, “The Changing Landscape of Healthcare and the American Consumer,” outlining the forward impact the current recession will have on how Americans research, purchase and use health care.
“Health care is costly, and people are rethinking how they take care of themselves in order to conserve funds,” Thom Blischok, president, consulting and innovation, IRI, wrote in the opening of the report. “Instead of sticking with their tried-and-true healthcare options, consumers are aggressively seeking affordable solutions for health and wellness, both in terms of how they obtain care and in the healthcare products they choose.”
And while Americans are changing how they choose health care, the Food and Drug Administration is “flexing its regulatory muscles again.” And while the new FDA activism is expected to make medicines and supplements safer, it also has the potential to add significant costs overall — including added costs in drug development as well as added costs to keep those medicines already approved on store or pharmacy shelves.